Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) have been given an average recommendation of “Moderate Buy” by the seven research firms that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating on the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $72.6667.

ELVN has been the subject of several research analyst reports. Stifel Nicolaus boosted their target price on Enliven Therapeutics from $80.00 to $82.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Mizuho raised their target price on Enliven Therapeutics from $45.00 to $62.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Friday, July 17th. Guggenheim cut their price target on shares of Enliven Therapeutics from $80.00 to $78.00 and set a “buy” rating on the stock in a research report on Thursday, August 6th. Finally, HC Wainwright increased their price target on Enliven Therapeutics from $56.00 to $64.00 and gave the stock a “buy” rating in a report on Thursday, July 9th.

Insiders Place Their Bets

In related news, Director Lori Anne Kunkel sold 10,000 shares of Enliven Therapeutics stock in a transaction on Monday, July 6th. The shares were sold at an average price of $50.49, for a total value of $504,900.00. Following the completion of the sale, the director owned 41,884 shares of the company’s stock, valued at approximately $2,114,723.16. This trade represents a 19.27% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Benjamin Hohl sold 6,018 shares of the business’s stock in a transaction dated Friday, July 17th. The stock was sold at an average price of $52.64, for a total transaction of $316,787.52. Following the sale, the chief financial officer directly owned 46,054 shares of the company’s stock, valued at approximately $2,424,282.56. The trade was a 11.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 190,831 shares of company stock worth $10,991,723. 3.00% of the stock is currently owned by company insiders.

Institutional Trading of Enliven Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in ELVN. BlackRock Inc. purchased a new stake in Enliven Therapeutics in the 2nd quarter valued at about $221,255,000. Vestal Point Capital LP boosted its stake in shares of Enliven Therapeutics by 230.2% in the 4th quarter. Vestal Point Capital LP now owns 3,830,000 shares of the company’s stock worth $58,982,000 after buying an additional 2,670,000 shares during the last quarter. Siren L.L.C. bought a new position in shares of Enliven Therapeutics in the first quarter valued at approximately $29,252,000. Jupiter Topco LLC bought a new position in Enliven Therapeutics in the 2nd quarter valued at $30,617,000. Finally, Affinity Asset Advisors LLC bought a new position in Enliven Therapeutics during the first quarter valued at about $23,007,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Stock Up 1.3%

Enliven Therapeutics stock opened at $58.82 on Friday. The stock has a market cap of $4.31 billion, a P/E ratio of -35.22 and a beta of 0.27. Enliven Therapeutics has a twelve month low of $14.78 and a twelve month high of $62.32. The company’s 50-day moving average price is $50.90 and its two-hundred day moving average price is $40.79.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.10). Equities analysts anticipate that Enliven Therapeutics will post -1.67 earnings per share for the current fiscal year.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.